AURA - CIK 0001501796
The table below shows Aura Biosciences, Inc.'s income statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - |
| Cost of revenue | - | - | - | - | - | - |
| Gross profit | - | - | - | - | - | - |
| R&D | $27.96M | $22.18M | $22.88M | $23.34M | $17.04M | $16.88M |
| SG&A |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $6.91M |
| $5.73M |
| $5.73M |
| $5.69M |
| $6.20M |
| $5.88M |
| Operating income | -$34.87M | -$27.91M | -$28.61M | -$29.04M | -$23.23M | -$22.76M |
| Income tax | $11.00K | $26.00K | $48.00K | $18.00K | $43.00K | - |
| Net income | -$33.69M | -$26.13M | -$27.02M | -$27.48M | -$21.04M | -$20.34M |
| EPS (diluted) | -$0.50 | -$0.40 | -$0.47 | -$0.55 | -$0.42 | -$0.41 |